Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial

Sherief Abd-Elsalam, Shaimaa Soliman, Eslam Saber Esmail, Mai Khalaf, Ehab F Mostafa, Mohammed A Medhat, Ossama Ashraf Ahmed, Mohamed Samir Abd El Ghafar, Mohamed Alboraie, Sahar M Hassany, Sherief Abd-Elsalam, Shaimaa Soliman, Eslam Saber Esmail, Mai Khalaf, Ehab F Mostafa, Mohammed A Medhat, Ossama Ashraf Ahmed, Mohamed Samir Abd El Ghafar, Mohamed Alboraie, Sahar M Hassany

Abstract

No specific treatment for COVID-19 infection is available up till now, and there is a great urge for effective treatment to reduce morbidity and mortality during this pandemic. We aimed to evaluate the effect of combining chloroquine/hydroxychloroquine (CQ/HCQ) and zinc in the treatment of COVID-19 patients. This was a randomized clinical trial conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection were randomized into two groups: group I (96) patients received both HCQ and zinc, and group II (95) received HCQ only. The primary endpoints were the recovery within 28 days, the need for mechanical ventilation, and death. The two groups were matched for age and gender. They had no significant difference regarding any of the baseline laboratory parameters or clinical severity grading. Clinical recovery after 28 days was achieved by 79.2% in the zinc group and 77.9% in zinc-free treatment group, without any significant difference (p = 0.969). The need for mechanical ventilation and the overall mortality rates did not show any significant difference between the 2 groups either (p = 0.537 and 0.986, respectively). The age of the patient and the need for mechanical ventilation were the only risk factors associated with the patients' mortality by the univariate regression analysis (p = 0.001 and < 0.001, respectively). Zinc supplements did not enhance the clinical efficacy of HCQ. More randomized studies are needed to evaluate the value of adding zinc to other therapies for COVID 19. ClinicalTrials.gov Identifier: NCT04447534.

Keywords: Antioxidants; COVID 19; Chloroquine; Treatment; Zinc.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

References

    1. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59:118–128. doi: 10.1007/s12026-014-8534-z.
    1. Liu J, Liao X, Qian S, et al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. 2020;26(6):1320–1323. doi: 10.3201/eid2606.200239.
    1. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi: 10.1016/S0140-6736(20)30154-9.
    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382(13):1199–1207. doi: 10.1056/NEJMoa2001316.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425–434. doi: 10.1016/S1473-3099(20)30086-4.
    1. WHO Coronavirus Disease (COVID-19) Dashboard available at: . Accessed 15 Oct 2020
    1. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69.
    1. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949.
    1. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D, Qian Z, Li T, Shen Y, Lu H. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215–219.
    1. Abd-Elsalam S, Esmail ES, Khalaf M, Abdo EF, Medhat MA, Abd el Ghafar MS, Ahmed OA, Soliman S, Serangawy GN, Alboraie M. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. Am J Trop Med Hyg. 2020;103:1635–1639. doi: 10.4269/ajtmh.20-0873.
    1. Magagnoli J, Narendran S, Pereira F et al (2020) Outcomes of Hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Med (N Y). 10.1016/j.medj.2020.06.001 Online ahead of print
    1. Sarin SK, Choudhury A, Lau GK et al (2020) Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study (APASL COVID-19 liver injury Spectrum study). Hepatol Int 1–11. 10.1007/s12072-020-10072-8 Online ahead of print
    1. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C, Eldin C, Tissot-Dupont H, Honoré S, Stein A, Jacquier A, Deharo JC, Chabrière E, Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, la Scola B, Parola P, Raoult D. Early treatment of COVID-19 patients with Hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738. doi: 10.1016/j.tmaid.2020.101738.
    1. Lazarczyk M, Favre M. Role of Zn2+ ions in host-virus interactions. J Virol. 2008;82:11486–11494. doi: 10.1128/JVI.01314-08.
    1. Frederickson CJ, Koh J-Y, Bush AI. The neurobiology of zinc in health and disease. Nat Rev Neurosci. 2005;6:449–462. doi: 10.1038/nrn1671.
    1. te Velthuis AJ, van den Worm SH, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6:e1001176. doi: 10.1371/journal.ppat.1001176.
    1. Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ. Chloroquine is a zinc ionophore. PLoS One. 2014;9:e109180. doi: 10.1371/journal.pone.0109180.
    1. Dabbagh-Bazarbachi H, Clergeaud G, Quesada IM, et al. Zinc ionophore activity of quercetin and epigallocatechin-gallate: from hepa 1-6 cells to a liposome model. J Agric Food Chem. 2014;62(32):8085–8093. doi: 10.1021/jf5014633.
    1. Marjot T, Moon AM, Cook JA et al (2020) Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol S0168-8278(20)33667–9. 10.1016/j.jhep.2020.09.024
    1. Abd-Elsalam S, Elkadeem M, Glal KA (2020) Chloroquine as chemoprophylaxis for COVID-19: will this work? Infect Disord Drug Targets. 10.2174/1871526520666200726224802 Online ahead of print
    1. Mohamed AA, Mohamed N, Mohamoud S et al (2020) SARS-CoV-2: the path of prevention and control. Infect Disord Drug Targets. 10.2174/1871526520666200520112848 Online ahead of print
    1. Pal A, Squitti R, Picozza M et al (2020) Zinc and COVID-19: basis of current clinical trials. Biol Trace Elem Res 1–11. 10.1007/s12011-020-02437-9 Online ahead of print
    1. Pawar A, Pal A (2020) Molecular and functional resemblance of dexamethasone and quercetin: a paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients. Phytother Res 10.1002/ptr.6886. 10.1002/ptr.6886 Online ahead of print
    1. Pal A, Pawar A, Goswami K, Sharma P, Prasad R. Hydroxychloroquine and Covid-19: a cellular and molecular biology based update. Indian J Clin Biochem. 2020;35(3):274–284. doi: 10.1007/s12291-020-00900-x.
    1. World Health Organization (2020) Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. (World Health Organization, 2020)
    1. Shah GS, Dutta AK, Shah D, Mishra OP. Role of zinc in severe pneumonia: a randomized double bind placebo controlled study. Ital J Pediatr. 2012;38:36. doi: 10.1186/1824-7288-38-36.
    1. Fiolet T, Guihur A, Rebeaud M et al Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and metaanalysis. 10.1016/j.cmi.2020.08.022

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner